Zogenix to Participate in the BofA Securities SMID Cap 2H21 Ideas Conference
August 03, 2021 16:05 ET
|
Zogenix, Inc
EMERYVILLE, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced...
Zogenix to Release Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 5
July 22, 2021 08:00 ET
|
Zogenix, Inc
EMERYVILLE, Calif., July 22, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that it will...
Zogenix Product FINTEPLA® (Fenfluramine) Recognized for Setting a New Standard for Dravet Syndrome Treatment Outcomes
July 21, 2021 08:00 ET
|
Zogenix, Inc
In Epilepsy & Behavior editorial, authors write that FINTEPLA data demonstrate “unprecedented level of seizure control” for treated patients living with Dravet syndrome, a severe, debilitating...
VIP Siblings and www.vipsibling.com, New Resources to Support Brothers & Sisters of Those Living with Severe, Rare Epilepsies, Now Available from Zogenix and 10 Advocacy Groups
July 14, 2021 16:01 ET
|
Zogenix, Inc
EMERYVILLE, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- Zogenix, a global biopharmaceutical company developing rare disease therapies, and ten U.S. advocacy groups today announced the launch of VIP...
Zogenix to Participate in Two Upcoming Investor Conferences
June 21, 2021 08:00 ET
|
Zogenix, Inc
EMERYVILLE, Calif., June 21, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that members...
Zogenix to Participate in the BofA Securities 2021 Healthcare Conference
May 11, 2021 16:01 ET
|
Zogenix, Inc
EMERYVILLE, Calif., May 11, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that Stephen J....
Zogenix Provides Corporate Update and Reports First Quarter 2021 Financial Results
May 06, 2021 16:01 ET
|
Zogenix, Inc
Continued positive momentum for U.S. launch of FINTEPLA® (fenfluramine) oral solution in Dravet syndrome, with total net product sales of $12.3 million and total revenue of $13.7 million in the first...
Zogenix Launches Global Access Program for FINTEPLA® (Fenfluramine) Oral Solution
April 27, 2021 08:00 ET
|
Zogenix, Inc
FINTEPLA is approved in the U.S. and European Union as an add-on therapy for the treatment of seizures associated with Dravet syndrome in patients aged two years and older.The new program supports...
Zogenix Presents New Data at Virtual AAN 2021 Showing Improved Executive Function in Lennox-Gastaut Syndrome (LGS) Patients Treated with FINTEPLA® (Fenfluramine) Oral Solution
April 22, 2021 08:01 ET
|
Zogenix, Inc
LGS is one of the most challenging developmental and epileptic encephalopathies to manage because of high seizure frequency and significant neurodevelopmental impairment.More LGS study patients...
Zogenix to Release First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 6
April 22, 2021 08:00 ET
|
Zogenix, Inc
EMERYVILLE, Calif., April 22, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that it will report its financial...